DARE · XBRL financial data

Dare Bioscience financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (DARE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	1,000	1,808*	9	22	42	—	—	—	—	—	—	—
Revenue from contracts with customers	1,000	1,808*	9	22	42	(64)*	25	(21)*	2	1,024*	152	188
Cost of revenue	—	—	—	—	—	year only	0	0	—	year only	242	320
Research and development	6,675	3,800*	3,329	4,909	2,657	3,311*	2,297	1,429	1,175	622*	660	242
Selling, general and administrative	—	—	—	—	—	year only	2,309	2,378	—	year only	2,249	2,594
General and administrative	2,697	3,155*	2,671	2,448	2,041	1,996*	2,309	2,378	2,499	—	—	—
Total operating expenses	9,396	6,979*	6,032	7,382	4,723	5,325*	4,607	3,807	3,674	2,199*	2,909	2,836
Operating income (loss)	(8,396)	(5,171)*	(6,022)	(7,359)	(4,681)	(5,388)*	(4,581)	(3,828)	(3,672)	(1,471)*	(2,999)	(2,968)
Other income (expense)	97	114*	(733)	(109)	(21)	(118)*	203	(189)	109	(277)*	(1)	(15)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(8,299)	(5,058)*	(6,755)	12,911	(4,703)	(5,506)*	(4,378)	(4,016)	(3,563)	(1,442)*	(3,000)	(2,983)
Earnings per share, basic‡ USD per share	(1.08)	(0.72)*	(0.84)	18.37	(0.55)	—	(0.50)	(0.45)	(0.28)	—	(0.21)	(0.20)
Earnings per share, diluted‡ USD per share	(1.08)	(0.72)*	(0.84)	18.25	(0.55)	—	(0.50)	(0.45)	(0.28)	—	(0.21)	(0.20)
Weighted average shares, basic‡ thousands of shares	7,585	7,180*	8,373	701	8,534	—	8,759	8,871	12,755	—	14,523	14,890
Weighted average shares, diluted‡ thousands of shares	7,585	7,180*	8,373	706	8,534	—	8,759	8,871	12,755	—	14,523	14,890

‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (July 2024); filings made before it reported them unadjusted.
† Share count changed about 1/12 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 12x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (DARE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	13,894	10,476	3,631	16,415	11,233	15,698	10,330	5,035	23,075	24,711	18,520	12,618
Total current assets	22,435	17,544	9,983	20,829	14,946	18,448	11,823	6,602	25,004	27,064	21,659	16,686
Property and equipment, net	59	656	52	322	706	1,336	1,485	1,652	1,657	1,559	1,449	1,420
Right-of-use asset	182	1,320	1,561	1,446	1,328	1,207	1,083	956	825	1,098	969	838
Total assets	25,054	21,282	13,013	23,606	18,059	22,101	18,619	12,980	30,749	32,475	27,828	22,370
Accounts payable	4,987	3,386	4,041	1,910	1,049	1,456	1,883	1,763	1,845	1,201	1,231	763
Accrued liabilities	5,293	2,889	1,370	1,254	1,851	3,043	1,772	2,524	2,325	725	529	449
Current portion of long-term debt	—	—	—	—	—	4	92	188	11	—	—	—
Total current liabilities	26,343	20,480	17,725	14,590	13,156	21,609	21,188	19,221	21,216	23,686	21,119	16,923
Lease liability, non-current	0	936	1,172	1,037	898	754	603	448	289	559	418	274
Total liabilities	27,343	26,330	24,012	20,935	19,543	28,113	28,183	25,713	27,891	29,632	27,094	22,930
Accumulated deficit	(166,178)	(171,236)	(177,991)	(165,081)	(169,783)	(175,290)	(179,668)	(183,684)	(187,247)	(188,689)	(191,689)	(194,672)
Total stockholders' equity	(2,289)	(5,048)	(10,999)	2,672	(1,484)	(6,012)	(9,564)	(12,733)	2,858	2,843	734	(560)
Total liabilities and equity	25,054	21,282	13,013	23,606	18,059	22,101	18,619	12,980	30,749	32,475	27,828	22,370
Common shares outstanding (cover page)‡ thousands of shares	8,210	8,378	8,421	712	8,700	8,850	8,850	13,480	14,289	14,560	14,980	15,290

‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (July 2024); filings made before it reported them unadjusted.
† Share count changed about 1/12 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 12x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (DARE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(8,299)	(5,058)*	(6,755)	12,911	(4,703)	(5,506)*	(4,378)	(4,016)	(3,563)	(1,442)*	(3,000)	(2,983)
Stock-based compensation	636*	620*	628	563*	524*	489*	377	359*	403*	357*	455	287*
Depreciation and amortization	—	—	11	15*	10*	6*	158	460*	482*	534*	555	572*
Net cash from operating activities	(7,974)*	(8,179)*	(6,813)	12,905*	(5,924)*	5,227*	(5,471)	(5,417)*	(442)*	1,444*	(5,521)	(6,775)*
Purchases of property and equipment	22*	607*	7	285*	(282)*	563*	157	(153)*	175*	207*	0	81*
Net cash from investing activities	(22)*	(607)*	(7)	(285)*	282*	(563)*	(157)	153*	(175)*	(207)*	0	(81)*
Proceeds from issuing common stock	—	—	—	—	—	year only	436	475*	—	year only	95	167*
Net cash from financing activities	8,576*	5,309*	14	115*	436*	(132)*	247	(44)*	18,650*	424*	(715)	951*
Net change in cash	565*	(3,418)*	(6,845)	12,749*	(5,182)*	4,466*	(5,368)	(5,295)*	18,040*	1,636*	(6,192)	(5,902)*

† Share count changed about 1/12 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 12x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Dare Bioscience	12,618	188	(6,775)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1,714	31*	(1,841)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Imunon	6,864	not reported	(3,025)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Armata Pharmaceuticals	23,952	not reported	(8,666)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Fibrogen	50,644	(1,474)	(3,991)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1,020	not reported	(5,841)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
Ovid Therapeutics	11,327	733	(17,594)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
vTv Therapeutics	86,643	0	(11,443)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Marimed	8,437	41,925	2,219*	403.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.